Advertisement

New Jersey Oncology Care Providers Form Astera Cancer Care, Join OneOncology


Advertisement
Get Permission

Bruno S. Fang, MD

Bruno S. Fang, MD

Edward J. Licitra, MD, PhD

Edward J. Licitra, MD, PhD

A group of 37 medical and radiation oncologists—along with a staff of cancer-care providers, led by Bruno S. Fang, MD, and Edward J. Licitra, MD, PhD, who currently constitute the Central Jersey Division of Regional Cancer Care Associates—are forming Astera Cancer Care, an independent and physician-owned multispecialty community oncology practice serving 12,000 new patients annually. The practice will join the OneOncology platform, making it the ninth practice to become part of the OneOncology partnership of independent community oncology practices.

Astera will consist of 26 medical oncologists, 11 radiation oncologists, 2 breast surgeons, 10 advance practice providers, and 3 PharmDs, who collectively have been caring for patients in Central New Jersey since 1981. The physicians have an average of more than 20 years of medical experience. 

Full Array of Oncology Treatments

The practice offers standard and advanced therapeutics, including chemotherapy, biologic therapy immunotherapies, and radiopharmaceuticals. These services are in addition to a total complement of radiation oncology treatment options, including proton therapy, brachytherapy, and radiosurgery.

Astera also has a robust clinical trial platform for cancer therapy, with one of the only community-based clinical trial programs in chimeric antigen receptor T-cell therapies in the nation. As part of the OneOncology network, the group will participate in OneR, OneOncology’s clinical trial network.

The practice has participated in Medicare’s value-based oncology program, the Oncology Care Model. Astera has also developed innovative episode-based payment models with commercial payers for the comprehensive delivery of medical and radiation oncology care for patients with early-stage breast cancer. The group has additional programs under development for lung, prostate, rectal, and head and neck cancers, along with several hematologic malignancies. 


Advertisement

Advertisement



Advertisement